Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin

被引:79
作者
Bottiger, Y [1 ]
Tybring, G [1 ]
Gotharson, E [1 ]
Bertilsson, L [1 ]
机构
[1] KAROLINSKA INST, HUDDINGE UNIV HOSP, DEPT MED LAB SCI & TECHNOL, DIV CLIN PHARMACOL, S-10401 STOCKHOLM, SWEDEN
关键词
D O I
10.1016/S0009-9236(97)90116-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: The metabolism of omeprazole includes hydroxylation catalyzed by CYP2C19 and, to a minor extent, sulfoxidation, presumably by CYP3A4. Sulfoxidation may be the predominant pathway in individuals devoid of the genetically determined CYP2C19 activity. Ketoconazole is a known CYP3A4 inhibitor in daily doses from 200 to 400 mg, In this study ketoconazole was used as a probe to investigate the extent to which CYP3A4 is involved in omeprazole metabolism in vivo. Methods: A single oral 20 mg dose of omeprazole before and after four daily doses of 200, 100, or 50 mg ketoconazole was given to 10 healthy subjects, previously phenotyped as poor or extensive metabolizers of S-mephenytoin. Concentrations of omeprazole, 5-hydroxyomeprazole, omeprazole sulfone, and ketoconazole were analyzed with, reversed-phase HPLC methods in plasma samples collected repeatedly for 12 hours after dosing. Results: After intake of 20 mg omeprazole with 0, 50, 100, and 200 mg ketoconazole, mean values for omeprazole sulfone area under the plasma concentration versus time curve from 0 to 6 hours [AUC(0-6)] were 482, 206, 167, and <100 nmol/L . hr in extensive metabolizers and 3160, 2430, 937, and 534 nmol/L . hr in poor metabolizers, respectively. Mean omeprazole AUC(0-6) increased from 1660 to 2265 nmol/L . hr in extensive metabolizers and from 7715 to 15319 nmol/L . hr in poor metabolizers after intake of 200 mg ketoconazole. Conclusions: An oral daily dose of 100 to 200 mg ketoconazole is sufficient to provide a marked inhibition of the formation of the omeprazole: sulfone in both extensive and poor metabolizers and leads to a doubling of omeprazole levels in poor metabolizers, whereas 50 mg ketoconazole provides only partial inhibition, We concluded that CYP3A4-catalyzes the sulfoxidation of omeprazole and that this is the predominant metabolic pathway of omeprazole in poor metabolizers of S-mephenytoin.
引用
收藏
页码:384 / 391
页数:8
相关论文
共 19 条
[1]   HYDROXYLATION POLYMORPHISMS OF DEBRISOQUINE AND MEPHENYTOIN IN EUROPEAN POPULATIONS [J].
ALVAN, G ;
BECHTEL, P ;
ISELIUS, L ;
GUNDERTREMY, U .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (06) :533-537
[2]   POLYMORPHIC HYDROXYLATION OF S-MEPHENYTOIN AND OMEPRAZOLE METABOLISM IN CAUCASIAN AND CHINESE SUBJECTS [J].
ANDERSSON, T ;
REGARDH, CG ;
LOU, YC ;
ZHANG, Y ;
DAHL, ML ;
BERTILSSON, L .
PHARMACOGENETICS, 1992, 2 (01) :25-31
[3]   Pharmacokinetics, metabolism and interactions of acid pump inhibitors - Focus on omeprazole, lansoprazole and pantoprazole [J].
Andersson, T .
CLINICAL PHARMACOKINETICS, 1996, 31 (01) :9-28
[4]   IDENTIFICATION OF HUMAN LIVER CYTOCHROME-P450 ISOFORMS MEDIATING OMEPRAZOLE METABOLISM [J].
ANDERSSON, T ;
MINERS, JO ;
VERONESE, ME ;
TASSANEEYAKUL, W ;
TASSANEEYAKUL, W ;
MEYER, UA ;
BIRKETT, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 36 (06) :521-530
[5]   SLOW OMEPRAZOLE METABOLIZERS ARE ALSO POOR S-MEPHENYTOIN HYDROXYLATORS [J].
ANDERSSON, T ;
REGARDH, CG ;
DAHLPUUSTINEN, ML ;
BERTILSSON, L .
THERAPEUTIC DRUG MONITORING, 1990, 12 (04) :415-416
[6]   PRONOUNCED DIFFERENCES BETWEEN NATIVE CHINESE AND SWEDISH POPULATIONS IN THE POLYMORPHIC HYDROXYLATIONS OF DEBRISOQUIN AND S-MEPHENYTOIN [J].
BERTILSSON, L ;
LOU, YQ ;
DU, YL ;
LIU, Y ;
KUANG, TY ;
LIAO, XM ;
WANG, KY ;
REVIRIEGO, J ;
ISELIUS, L ;
SJOQVIST, F .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (04) :388-397
[7]   Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype [J].
Chang, M ;
Dahl, ML ;
Tybring, G ;
Gotharson, E ;
Bertilsson, L .
PHARMACOGENETICS, 1995, 5 (06) :358-363
[8]   In vitro and in vivo studies on the disposition of mirtazapine in humans [J].
Dahl, ML ;
Voortman, G ;
Alm, C ;
Elwin, CE ;
Delbressine, L ;
Vos, R ;
Bogaards, JJP ;
Bertilsson, L .
CLINICAL DRUG INVESTIGATION, 1997, 13 (01) :37-46
[9]   THE EFFECTS OF KETOCONAZOLE ON THE INTESTINAL METABOLISM AND BIOAVAILABILITY OF CYCLOSPORINE [J].
GOMEZ, DY ;
WACHER, VJ ;
TOMLANOVICH, SJ ;
HEBERT, MF ;
BENET, LZ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (01) :15-19
[10]   INTERACTION BETWEEN TOLBUTAMIDE AND KETOCONAZOLE IN HEALTHY-SUBJECTS [J].
KRISHNAIAH, YSR ;
SATYANARAYANA, S ;
VISWESWARAM, D .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (02) :205-207